Skip to main content
Premium Trial:

Request an Annual Quote

Matritech, Bruker Daltonics To Develop Mass Spec For Cancer Diagnostics

NEW YORK, May 20-Bruker Daltonics and Matritech said today that they will work together to develop an automated mass spectrometer for proteomics-based clinical cancer diagnostics.

 

The two companies will partner to adapt Bruker's MALDI-TOF spectrometer technology to perform tests for the early detection of prostate and breast cancer.

 

The resulting system will be "turn-key," said Matritech COO and president David Corbet in a statement, allowing clinical laboratories to deliver the company's proprietary tests to market quickly.

 

Financial details were not disclosed.

 

Matritech, based in Newton, Mass., develops proteomics-based diagnostics for early cancer detection. The company has identified markers associated with breast, bladder, prostate, cervical and colon cancers, and has a bladder cancer test currently on the market. The company is publicly owned.

 

Bruker Daltonics, based in Billerica, Mass., is a major provider of mass spectrometry and analysis systems.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.